WHO moves to update COVID-19 guideline after 'great news' in drug studies

The World Health Organization (WHO) is moving to update its guidelines on the treatment of people with COVID-19 to reflect the clinical trial results, which show that cheap, generic steroids can help protect acutely ill patients.

The test results, announced Tuesday, show dexamethasone used to reduce the inflammation of diseases such as arthritis in the 1960s, about one-third of the death rate in patients with the most severe chronic COVID-19 hospitalization. Decrease.

WHO's clinical guidance for treating new coronavirus-infected patients is targeted at physicians and other medical professionals, and the use of up-to-date data to inform clinicians about the best way to deal with the disease, from screening to discharge.

Although the results of the dexamethasone study are preliminary, the researchers behind the project suggest that drug deposition should quickly become standard care in severely injured patients.

Preliminary results shared with the WHO show that treatment on ventilators reduces mortality by up to one-third, and for patients who require only oxygen, mortality is reduced by one-fifth. I have gone.

This benefit was only seen in sick patients with COVID-19 and not in lactating patients.

The positive news is that coronavirus infections have accelerated in some places, including the US, and Beijing has canceled several flights to help spread the Chinese capital to new areas.

"COVID-19 is the first treatment that has been shown to reduce mortality in patients who require oxygen or ventilator support," WHO Director-General Tedros Adnom Ghebius said in a statement Tuesday. The agency said it is awaiting a full data analysis of the study in the coming days.

The agency stated that WHO is coordinating a meta-analysis to increase our overall understanding of this intervention. WHO's clinical guidance will be updated to reflect when and how they are used in COVID-19.

Post a Comment